Skip to Main Content

Investors who want to bet on China’s booming biopharma industry will soon be able to buy and sell a new basket of securities.

A new exchange-traded fund dedicated to the sector will begin trading on the Nasdaq stock exchange on Wednesday, under the ticker CHNA. The ETF comes from the biotech investor Brad Loncar, who earlier this year launched an index tracking the performance of China’s drug industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.